Studying the Senescent T Cell Features and Its Relationship with the Chemotherapy Efficacy in Young TNBC

Not yet recruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
T-Cell DysfunctionChemotherapy EffectAdverse Events
Interventions
DRUG

docetaxel, anthracycline, cyclophosphamide

"1. Participants were required to receive 6 cycles of TEC/TAC neoadjuvant chemotherapy, and radical mastectomy was required after chemotherapy.~2. 5ml peripheral venous blood was collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.~3. Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study."

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT06684054 - Studying the Senescent T Cell Features and Its Relationship with the Chemotherapy Efficacy in Young TNBC | Biotech Hunter | Biotech Hunter